Veru is trading 5.1% down at $2.43 as investors continue to lock in gains following its recent Novo Nordisk clinical supply deal and strong Q2 fiscal 2026 earnings.
- The stock’s slide extends a 7.9% drop from July 13, 2026, as the momentum from its recent partnership and earnings report fades.
- Selling pressure aligns with broader profit-taking across high-beta biotech stocks, with the biotech sector ETF (XBI) also under pressure.